about
Factors affecting the stability and repeatability of gamma camera calibration for quantitative imaging applications based on a retrospective review of clinical dataDose-finding study of 153Sm-EDTMP in patients with poor-prognosis osteosarcoma.Predicting hematologic toxicity in patients undergoing radioimmunotherapy with 90Y-ibritumomab tiuxetan or 131I-tositumomab124I PET-based 3D-RD dosimetry for a pediatric thyroid cancer patient: real-time treatment planning and methodologic comparisonStudy of the impact of tissue density heterogeneities on 3-dimensional abdominal dosimetry: comparison between dose kernel convolution and direct Monte Carlo methods.Estimates of radiation-absorbed dose to kidneys in patients treated with 90Y-ibritumomab tiuxetan.Arterial wall dosimetry for non-Hodgkin lymphoma patients treated with radioimmunotherapy.Fine-resolution voxel S values for constructing absorbed dose distributions at variable voxel sizeExtension of the biological effective dose to the MIRD schema and possible implications in radionuclide therapy dosimetryTandem dosing of samarium-153 ethylenediamine tetramethylene phosphoric acid with stem cell support for patients with high-risk osteosarcoma.Development and evaluation of convergent and accelerated penalized SPECT image reconstruction methods for improved dose-volume histogram estimation in radiopharmaceutical therapy.Human biodistribution and radiation dosimetry of 82Rb.Tumor dosimetry and response for 153Sm-ethylenediamine tetramethylene phosphonic acid therapy of high-risk osteosarcoma.A bone marrow toxicity model for ²²³Ra alpha-emitter radiopharmaceutical therapy.Auger Radiopharmaceutical Therapy Targeting Prostate-Specific Membrane AntigenStrengths and Weaknesses of a Planar Whole-Body Method of (153)Sm Dosimetry for Patients with Metastatic Osteosarcoma and Comparison with Three-Dimensional Dosimetry.Three-dimensional radiobiological dosimetry of kidneys for treatment planning in peptide receptor radionuclide therapy.Preclinical evaluation of 86Y-labeled inhibitors of prostate-specific membrane antigen for dosimetry estimatesAn immunotolerant HER-2/neu transgenic mouse model of metastatic breast cancer.Three-dimensional imaging-based radiobiological dosimetry.Targeting aberrant DNA double-strand break repair in triple-negative breast cancer with alpha-particle emitter radiolabeled anti-EGFR antibody.Bortezomib-induced enzyme-targeted radiation therapy in herpesvirus-associated tumors.Radioimmunotherapy of breast cancer metastases with alpha-particle emitter 225Ac: comparing efficacy with 213Bi and 90Y.(2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted α-Particle Radiopharmaceutical Therapy.Three-dimensional radiobiological dosimetry (3D-RD) with 124I PET for 131I therapy of thyroid cancer.Modelling and dosimetry for alpha-particle therapy.Pharmacokinetics, microscale distribution, and dosimetry of alpha-emitter-labeled anti-PD-L1 antibodies in an immune competent transgenic breast cancer modelRedefining relative biological effectiveness in the context of the EQDX formalism: implications for alpha-particle emitter therapy.Depth-dependent concentrations of hematopoietic stem cells in the adult skeleton: Implications for active marrow dosimetry.Comparison of quantitative Y-90 SPECT and non-time-of-flight PET imaging in post-therapy radioembolization of liver cancer.A gamma camera count rate saturation correction method for whole-body planar imaging.A nephron-based model of the kidneys for macro-to-micro α-particle dosimetry.Improved dose-volume histogram estimates for radiopharmaceutical therapy by optimizing quantitative SPECT reconstruction parameters.A treatment planning method for sequentially combining radiopharmaceutical therapy and external radiation therapy.Three-dimensional radiobiologic dosimetry: application of radiobiologic modeling to patient-specific 3-dimensional imaging-based internal dosimetry.Calculation of the biological effective dose for piecewise defined dose-rate fitsA model of cellular dosimetry for macroscopic tumors in radiopharmaceutical therapy.Radiobiologic optimization of combination radiopharmaceutical therapy applied to myeloablative treatment of non-Hodgkin lymphoma.Quantitative impact of changes in marrow cellularity, skeletal size, and bone mineral density on active marrow dosimetry based upon a reference model.Combined model-based and patient-specific dosimetry for 18F-DCFPyL, a PSMA-targeted PET agent.
P50
Q30977013-7FD49A0A-DB8D-48FA-8915-29519D77E5FCQ33383964-B6189BB2-3BA1-40DA-9E4C-563643B16D03Q33392939-7D62F791-1A66-4C17-AD35-C9BEF151FD45Q33749165-6D16743F-FA4F-441F-A284-28E235C685EEQ33768719-D53DD3DF-2E59-488A-BE74-89D38E766C25Q34117144-F6685A67-8E01-4AE9-B54C-954A3051B3F9Q34255798-EF275C53-CBF1-4D03-8D28-BDF8074C8A2CQ34281098-7408968A-5A0F-4445-9395-17A2802CA2F0Q34282486-89C10587-25C1-4D5D-A6C8-F97812B5C3E6Q34348226-11000496-8D85-4EB4-94CA-A74FBB5004C9Q34563194-00ABE633-A2FB-4042-AC50-46495BA1690BQ35212024-1AD92422-F49F-416D-8AC1-682EE1227322Q35792772-79EF70CE-E39B-4A48-AB3A-675D435E324CQ36235572-437BB485-32CE-4398-9A68-D7B1C4B0A731Q36252485-19C5E363-AC0D-4D7B-9A04-3CB211EEB898Q36297804-260C980E-DAE2-4A4A-B529-D47F5626938DQ36300599-9EB51F87-1DC7-465D-A33F-3FDB97BD6EC3Q36928870-74DC8CCA-2F7A-4CFE-9965-DA52AB58725CQ36942958-22041813-C77C-43EC-9919-E6FB5ECD590AQ37002485-288B4C8B-4323-48DE-9F90-6017477D92DBQ37244880-8E64E8B9-6CAD-4C8E-8A42-464323F48D20Q37259751-66C6AC05-4D21-48C5-B56A-66AE20062925Q37460994-702780C7-C286-459C-988B-4197C1E3F8E5Q37722429-92F51B75-0930-4319-807D-8E529DE6E59FQ37864164-155C330A-1195-4671-ABE6-4FAB88D640ACQ37971507-693E807B-27F9-4A8E-8907-406D6E4260E0Q38672855-8D88A382-DAF6-4CAA-9A8D-54EB668FC57CQ38724752-A188E685-B17A-464B-BDCD-585B69B18270Q38992783-1E6CDECC-A43F-4049-87B0-71A810100323Q39248616-3950A7E8-D92F-48CB-95EB-B0D9883AE758Q39774521-22892992-5660-4D6B-8571-A4A351BFF647Q40254341-2829198F-2681-4214-8E76-EBB9F98F417FQ42093398-1D79EBDF-186B-4A7D-AF18-AF3C2E7B92F2Q42122579-ACA2EE33-9C38-4EA4-B648-417AD70F84B5Q42129021-2F31E5B4-EA20-48CA-9B81-980828D57B4AQ42543642-CCBE8948-D984-46C5-B3EE-BD4DA12A61BCQ42763210-0C47B33D-8AEA-4E97-BBCB-3B1AA977C05EQ42836462-8ABECF4C-4225-4493-94E3-89910B8014FEQ47242021-1929A42F-DE6C-4339-9ACC-287A6DC6FC70Q49827187-3D9E18BB-12EE-4363-904B-CF9FF6AC0A7D
P50
name
Robert F Hobbs
@en
type
label
Robert F Hobbs
@en
prefLabel
Robert F Hobbs
@en